Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;56(6):697-701.
doi: 10.1177/0018578720946767. Epub 2020 Jul 27.

Off-Label Use of Intravenous Olanzapine for Agitation After Neurologic Injury

Yuwei V Tsai  1 , John H Fawzy  2 , Joseph B Durkin  2 , Janine E Then  2 , Cory B McGinnis  2
Affiliations

Off-Label Use of Intravenous Olanzapine for Agitation After Neurologic Injury

Yuwei V Tsai et al. Hosp Pharm. 2021 Dec.

Abstract

Background: Small studies have described the off-label use of intravenous (IV) olanzapine for the management of acute agitation. Objective: The purpose of this study was to evaluate the efficacy and safety of IV olanzapine to manage acutely agitated patients with neurological injuries. Methods: This was a retrospective analysis of IV olanzapine use in patients admitted to the neurotrauma and neurovascular intensive care units at a single academic center. The primary endpoint was the requirement of additional IV olanzapine, IV benzodiazepine, or IV haloperidol within 60 minutes from the time of first IV olanzapine dose. Secondary safety endpoints included QTc prolongation and respiratory depression. Results: Forty-six patients received IV olanzapine during the study period. One patient required an additional dose of IV olanzapine and two patients received benzodiazepine or antipsychotic agents within 60 minutes of IV olanzapine administration. One patient had a post-administration QTc level >500 ms. Two patients had an increased oxygen requirement, but none required intubation. Conclusion: IV olanzapine appears to be efficacious in reducing the need for sedatives and antipsychotics with low risk for QTc prolongation and respiratory depression in acutely agitated patients with neurological injuries.

Keywords: agitation; critically ill patients; delirium; neurological injuries; olanzapine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Eli Lilly and Company. Olanzapine [package insert]. Indianapolis, IN: Eli Lilly and Company; 1997.
    1. Devlin JW, Skrobik Y, Gelinas C, et al.. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleepy disruption in adult patients in the ICU. Crit Care Med. 2019;46(9):e825. - PubMed
    1. Lorenzo MP, Burgess J, Darko W. Intravenous olanzapine in a critically ill patient: an evolving route of administration. Hosp Pharm. 2020;55(2):108-111. - PMC - PubMed
    1. Taylor DM, Yap CYL, Knott JC, et al.. Midazolam-droperidol, droperidol, or olanzapine for acute agitation: a randomized clinical trial. Ann Emerg Med. 2017;69(3):318-326.e1. - PubMed
    1. Martel ML, Klein LR, Rivard RL, et al.. A large retrospective cohort of patients receiving intravenous olanzapine in the emergency department. Acad Emerg Med. 2016;23(1):29-35. - PubMed

LinkOut - more resources